Adrenal Suppression with Aminoglutethimide. I. Differential Effects of Aminoglutethimide on Glucocorticoid Metabolism as a Rationale for Use of Hydrocortisone12
Abstract
The morbidity resulting from surgical adrenalectomy in patients with metastatic breast carcinoma has limited the use of this procedure to highly selected patients. Consequently, a chemical method of adrenal inhibition was developed which used aminoglutethimide to block cholesterol to pregnenolone conversion and dexamethasone as replacement glucocorticoid. This regimen effectively lowered urinary free cortisol excretion but was complicated by a drug interaction in which aminoglutethimide accelerated the metabolism of dexamethasone and reduced its bioavailability. Theoretically, replacement of dexamethasone with a glucocorticoid not subject to drug altered degradation would eliminate this drug interaction and simplify therapy. In order to determine whether hydrocortisone could be used, the metabolism and biological activity of this glucocorticoid was evaluated before and during aminoglutethimide administration. The plasma half-life, volume of distribution and metabolic clearance rate of hydrocortisone as determined by the single injection technique were not significantly altered by aminoglutethimide. The biopotency of hydrocortisone as reflected by its ability to suppress ACTH below basal levels was also retained during aminoglutethimide administration while that of dexamethasone was not. In order to evaluate the effectiveness of hydrocortisone in the aminoglutethimide regimen, a method was required for monitoring adrenal cortical function which was independent of glucocorticoid secretion. Plasma dehydroepiandrosterone-sulfate (DHA-S) levels were highly correlated (r – 0.79, P < .001) with urinary free cortisol excretion under basal and suppressed conditions. Plasma DHA-S was therefore used to establish the adrenal inhibiting effects of various doses of dexamethasone and hydrocortisone in patients receiving aminoglutethimide. A fixed dosage combination of 40 mg of hydrocortisone and 1000 mg of aminoglutethimide appeared to produce maximum suppression of DHA-S to levels 93% lower than basal. Negative nitrogen balance was not observed in patients receiving 20-60 mg of hydrocortisone along with aminoglutethimide, indicating a lack of major pharmacologic side effects of the administered glucocorticoid. A regimen for adrenal suppression using hydrocortisone and aminoglutethimide was developed which is simple and effective and should allow wide applicability without extensive endocrine monitoring in patients with metastatic breast carcinoma.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Aminoglutethimide is an inhibitor of CYP11A1 and CYP11B1 and was initially introduced as an antiepileptic medication.
“Aminoglutethimide is an inhibitor of CYP11A1 and CYP11B1 and was initially introduced as an antiepileptic medication (322, 323).”
From Adrenocortical carcinoma (2014) · cites this paper as [322]
Cited by
Sorted by citations
Else, T., Kim, A. C., Sabolch, A., Raymond, V. M., Kandathil, A., Caoili, E. M., Jolly, S., Miller, B. S., Giordano, T. J., & Hammer, G. D. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1029 · Cited by 892 · see citing works
Santen, R. J., Santner, S. J., DAVIS, B., Veldhuis, J. D., SAMOJLIK, E., & Ruby, E. B. (1978) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-47-6-1257 · Cited by 342 · see citing works
Self-citationKetoconazole and Other Imidazole Derivatives as Inhibitors of Steroidogenesis
Feldman, D. (1986) · Endocrine Reviews · doi:10.1210/edrv-7-4-409 · Cited by 216 · see citing works
Santen, R. J., Worgul, T. J., SAMOJLIK, E., Interrante, A., Boucher, A. E., Lipton, A., Harvey, H. A., White, D. S., Smart, E. K., Cox, C., et al. (1981) · New England Journal of Medicine · doi:10.1056/nejm198109033051003 · Cited by 203 · see citing works
Self-citationAminoglutethimide as Treatment of Postmenopausal Women with Advanced Breast Carcinoma
Santen, R. J., Worgul, T. J., Lipton, A., HARVEY, H., Boucher, A. E., SAMOJLIK, E., & Wells, S. A. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-96-1-94 · Cited by 171 · see citing works
Self-citationTissue production of androgens in women with acne
Lookingbill, D. P., Horton, R., Demers, L. M., Egan, N., Marks, J. G., & Santen, R. J. (1985) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(85)70067-9 · Cited by 123 · see citing works
Self-citationThe estrogenic and antiestrogenic activities of androgens in female target tissues.
Rochefort, H., & Garcia, M. (1983) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(83)90013-x · Cited by 107 · see citing works
Mechanisms of Action of Aminoglutethimide as Endocrine Therapy of Breast Cancer
Lønning, P. E., & Kvinnsland, S. (1988) · Drugs · doi:10.2165/00003495-198835060-00005 · Cited by 102 · see citing works
DHEAS as a new diagnostic tool
Leowattana, W. (2004) · Clinica Chimica Acta · doi:10.1016/j.cccn.2003.10.031 · Cited by 96 · see citing works
Weinstein (1982) · doi:10.1002/1097-0142(19821201)50:11
Self-citationMedical Adrenalectomy with Aminoglutethimide
Wells, S. A., Santen, R. J., Lipton, A., Haagensen, D. E., Ruby, E. B., Harvey, H. A., & Dilley, W. G. (1978) · Annals of Surgery · doi:10.1097/00000658-197805000-00004 · Cited by 93 · see citing works
Self-citationBarone, R. M., Shamonki, I. M., Siiteri, P. K., & Judd, H. L. (1979) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-49-5-672 · Cited by 88 · see citing works
High-dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma
Lenhard, R. E., Oken, M. M., Barnes, J. M., Humphrey, R. L., Glick, J. H., & Silverstein, M. N. (1984) · Cancer · doi:10.1002/1097-0142(19840401)53:7 · Cited by 54 · see citing works
Self-citationSerum Aminoglutethimide Levels: Studies of Serum Half‐Life, Clearance, and Patient Compliance
Murray, F. T., Santner, S. J., SAMOJLIK, E., et al. (1979) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1979.tb01640.x · Cited by 79 · see citing works
Self-citationHypercortisolemia and Infection
Fareau, G. G., & Vassilopoulou‐Sellin, R. (2007) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2007.06.001 · Cited by 75 · see citing works
SAMOJLIK, E., Veldhuis, J. D., Wells, S. A., & Santen, R. J. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109705 · Cited by 71 · see citing works
Self-citationAnti, M., Marra, G., Rapaccini, G., Rumi, C., Bussa, S., Fadda, G., Vecchio, F., Valenti, A., Percesepe, A., Pompili, M., et al. (1994) · Cancer · doi:10.1002/1097-0142(19940115)73:2 · Cited by 50 · see citing works
EFFECTS OF AMINOGLUTETHIMIDE ON ADRENAL STEROID SECRETION
Vermeulen, A., Paridaens, R., & Heuson, J.-C. (1983) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1983.tb00044.x · Cited by 69 · see citing works
Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery
Rosen, G., Marcove, R. C., Caparros, B., Nirenberg, A., Kosloff, C., & Huvos, A. G. (1979) · Cancer · doi:10.1002/1097-0142(197906)43:6 · Cited by 582 · see citing works
Self-citationWorgul, T. J., Santen, R. J., SAMOJLIK, E., et al. (1983) · The Journal of Urology · doi:10.1016/s0022-5347(17)51916-3 · Cited by 59 · see citing works
Self-citationIngle, J. N., Green, S., Ahmann, D. L., Long, H. J., Edmonson, J. H., Rubin, J., Chang, M. N., & Creagan, E. T. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.6.958 · Cited by 56 · see citing works
Lønning, P. E., Kvinnsland, S., Thorsen, T., & Ueland, P. M. (1987) · Clinical Pharmacokinetics · doi:10.2165/00003088-198713060-00004 · Cited by 54 · see citing works
Correlation of Serum 3α-Androstanediol Glucuronide with Acne and Chest Hair Density in Men
Lookingbill, D. P., Egan, N., Santen, R. J., & DEMERS, L. M. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-67-5-986 · Cited by 51 · see citing works
Self-citationAromatase in breast cancer and the role of aminoglutethimide and other aromatase inhibitors
Brodie, A. M. H., Santen, R. J., & Henderson, I. (1986) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(86)80003-8 · Cited by 47 · see citing works
Self-citationMurphy, B. E. P., GHADIRIAN, A. M., & Dhar, V. (1998) · The Canadian Journal of Psychiatry · doi:10.1177/070674379804300307 · Cited by 42 · see citing works
Psychologic adaptation to breast cancer
Holland, J. C., & Mastrovito, R. C. (1980) · Cancer · doi:10.1002/1097-0142(19800815)46:4+ · Cited by 49 · see citing works
Self-citationAutoradiography of cellular glycoproteins reveals histogenesis of bronchogenic adenocarcinomas
Dermer, G. B. (1981) · Cancer · doi:10.1002/1097-0142(19810415)47:8 · Cited by 8 · see citing works
Santen, R. J., Wells, S. A., COHN, N., Demers, L. M., Misbin, R. I., & Foltz, E. L. (1977) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-45-4-739 · Cited by 41 · see citing works
Self-citationStructure-Activity Relationships for Non-Steroidal Inhibitors of Aromatase
Banting, L., Smith, H. J., James, M., et al. (1988) · Journal of enzyme inhibition · doi:10.3109/14756368809040728 · Cited by 38 · see citing works
Santen, R. J. (1981) · Breast Cancer Research and Treatment · doi:10.1007/bf01806259 · Cited by 38 · see citing works
Self-citationMetabolism of steroid-modifying anticancer agents
Robinson, S. P., & Jordan, V. C. (1988) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(88)90112-x · Cited by 36 · see citing works
Medical management of Cushing disease
Gross, B. A., Mindea, S. A., Pick, A. J., Chandler, J. P., & Batjer, H. H. (2007) · Neurosurgical FOCUS · doi:10.3171/foc.2007.23.3.12 · Cited by 34 · see citing works
Haynes, B. P., Jarman, M., Dowsett, M., et al. (1991) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00688859 · Cited by 26 · see citing works
“Aminoglutethimide (AG) is the only widely used agent having this mechanism of action [15] but it also inhibits an early step in steroidogenesis, cholesterol side-chain cleavage (CSCC), as well as ll~-hydroxylase activity necessitating corticosteroid replacement therapy [5, 25 ].”
BackgroundAminoglutethimide in Advanced Prostatic Carcinoma
Harnett, P. R., Raghavan, D., Caterson, I. D., Pearson, B., Watt, H., Teriana, N., Coates, A. S., & COOREY, G. J. (1987) · British Journal of Urology · doi:10.1111/j.1464-410x.1987.tb04641.x · Cited by 23 · see citing works
Evidence that brain aromatization regulates LH secretion in the male dog
Worgul, T. J., Santen, R. J., SAMOJLIK, E., et al. (1981) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1981.241.3.e246 · Cited by 21 · see citing works
Self-citationTreatment Options in Cushing's Disease
Rizk, A., Honegger, J. B., Milian, M., & Psaras, T. (2012) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s6198 · Cited by 19 · see citing works
Pros and cons of aminoglutethimide for advanced postmenopausal breast cancer
Bruning, P., Bonfrèr, J., Engelsman, E., Hamersma-v.d. Linden, E., de Jong-Bakker, M., & Nooyen, W. (1984) · Breast Cancer Research and Treatment · doi:10.1007/bf01806041 · Cited by 18 · see citing works
“increase, instead of a decrease, of A and T (12, 13).”
BackgroundGoss, P. E., Jarman, M., & Griggs, L. J. (1985) · British Journal of Cancer · doi:10.1038/bjc.1985.37 · Cited by 17 · see citing works
Bruning, P. F., Bonfrer, J. M. G., Hart, A. A. M., et al. (1989) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(89)90032-1 · Cited by 17 · see citing works
Beretta, K., Hoeffken, K., Kvinnsland, S., et al. (1990) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a057795 · Cited by 16 · see citing works
Chouinard, G., Bélanger, M., Beauclair, L., et al. (1996) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(96)00084-x · Cited by 15 · see citing works
Acute Effects of Aminoglutethimide on Testicular Steroidogenesis in Normal Men*
Santen, R. J., Cohn, N., Misbin, R. I., SAMOJLIK, E., & Foltz, E. L. (1979) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-49-4-631 · Cited by 15 · see citing works
Self-citationMECHANISM OF ACTION OF AMINOGLUTETHIMIDE IN BREAST CANCER
Santen, R. J., Veldhuis, J., SAMOJLIK, E., et al. (1979) · The Lancet · doi:10.1016/s0140-6736(79)90484-7 · Cited by 14 · see citing works
Self-citationMedical Adrenalectomy for Treatment of Metastatic Breast Carcinoma
Santen, R. J., & SAMOJLIK, E. (1979) · Springer eBooks · doi:10.1007/978-1-4899-2663-0_3 · Cited by 14 · see citing works
Self-citationDevelopment of tolerance to the CNS effects of aminoglutethimide in mice
Ahmad, B., & Nicholls, P. J. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90282-b · Cited by 13 · see citing works
Aminoglutethimide stimulates extra adrenal δ-4-androstenedione production
Badder, E. M., Lerman, S. H., & Santen, R. J. (1983) · Journal of Surgical Research · doi:10.1016/0022-4804(83)90086-0 · Cited by 12 · see citing works
Self-citationPyridoglutethimide [3-ethyl-3-(4-pyridyl)-piperidine-2,6-dione], an analogue of aminoglutethimide
Seago, A., Goss, P. E., Griggs, L. J., et al. (1986) · Biochemical Pharmacology · doi:10.1016/0006-2952(86)90485-5 · Cited by 12 · see citing works
Inhibition of aromatase activity in the rat by aminoglutethimide and related compounds
Pourgholami, M. H., Nicholls, P. J., Smith, H. J., et al. (1987) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(87)90094-x · Cited by 12 · see citing works
Bruning, P. F., Bonfrer, J. M. G., Jong‐Bakker, M. D., & Nooyen, W. J. (1984) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(84)90282-6 · Cited by 11 · see citing works
Dowsett, M., Mehta, A., Cantwell, B. M. J., et al. (1991) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(91)90131-v · Cited by 10 · see citing works
Biological markers for breast carcinoma
Waalkes, T. P., Enterline, J. P., Shaper, J. H., Abeloff, M. D., & Ettinger, D. S. (1984) · Cancer · doi:10.1002/1097-0142(19840201)53:3+ · Cited by 49 · see citing works
Endocrine therapy in the management of prostatic cancer
Greenberg, E. J. (1980) · Clinics in Endocrinology and Metabolism · doi:10.1016/s0300-595x(80)80039-9 · Cited by 9 · see citing works
Wells, S. A., Worgul, T. J., SAMOJLIK, E., et al. (1982) · PubMed · Cited by 9 · see citing works
Self-citationAlexieva-Figusch, J., de Jong, F. H., Lamberts, S. W. J., et al. (1987) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(87)90119-2 · Cited by 9 · see citing works
Bezwoda, W. R. (1990) · British Journal of Urology · doi:10.1111/j.1464-410x.1990.tb14903.x · Cited by 8 · see citing works
Hefnawy, M. (2000) · Journal of Liquid Chromatography & Related Technologies · doi:10.1081/jlc-100101489 · Cited by 8 · see citing works
Aboul-Enein, H. Y., Bakr, S. A., & Nicholls, P. J. (1992) · Journal of Liquid Chromatography · doi:10.1080/10826079208016329 · Cited by 8 · see citing works
Carella, M. J., Dimitrov, N. V., Gossain, V. V., et al. (1994) · Metabolism · doi:10.1016/0026-0495(94)90121-x · Cited by 7 · see citing works
The pharmacologic control of adrenal steroidogenesis
Ontjes, D. A. (1980) · Life Sciences · doi:10.1016/0024-3205(80)90586-x · Cited by 7 · see citing works
Medical Therapy for Cushing’s Disease – Past and Future Modes of Treatment
Alexandraki, K., Grossman, A. B., & Endocrinology, S. I. (2008) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2008.04.02.74 · Cited by 5 · see citing works
SAMOJLIK, E., Santen, R. J., Kirschner, M. A., et al. (1982) · PubMed · Cited by 5 · see citing works
Self-citationAminoglutethimide in the management of metastatic breast cancer
Savaraj, N., & Troner, M. B. (1980) · Medical and Pediatric Oncology · doi:10.1002/mpo.2950080307 · Cited by 5 · see citing works
Worgul, T. J., Kendall, J. W., & Santen, R. J. (1981) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-53-4-879 · Cited by 4 · see citing works
Self-citationHefnawy, M. (2003) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/s0731-7085(02)00702-1 · Cited by 4 · see citing works
Treatment of ER-positive breast cancer with FDA-approved aromatase inhibitors
Kim, N., & Lukong, K. E. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101134 · Cited by 4 · see citing works
Crivellari, D., Galligioni, E., Frustaci, S., et al. (1989) · Cancer Investigation · doi:10.3109/07357908909038277 · Cited by 1 · see citing works
Clinical Applications in the Area of Contraceptive Development
Ryan, K. J. (1979) · Advances in experimental medicine and biology · doi:10.1007/978-1-4684-3474-3_82
Nazareth, W., Jones, G. W., James, M. I., et al. (1986) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1986.tb14334.x
Pharmacotherapy for Hormone Excess in Adrenocortical Carcinoma
Auchus, R. J. (2009) · Springer eBooks · doi:10.1007/978-0-387-77236-3_23 · Cited by 1 · see citing works
“Aminoglutethimide also inhibits CYP11B1, which further blunts cortisol production, as well as aromatase at higher doses, which mandates concurrent hydrocortisone replacement when used to treat breast cancer [ 46 ].”
BackgroundHamaker, L., & Jabbour, S. A. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3291-5.50045-7
(1981) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1981.tb03556.x
History of the early development of aromatase inhibitors for treatment of breast cancer
Santen, R. J., & Demers, L. (2026) · Breast Cancer Research and Treatment · doi:10.1007/s10549-026-08059-4
Self-citation
- Authors
- SANTEN, R. J., WELLS, S. A., RUNIC, S., GUPTA, C., KENDALL, J., RUDY, E. B., & SAMOJLIK, E.
- Affiliations
- Pennsylvania State University (US)
- Oregon Health & Science University (US)
- ORCID
- SANTEN, RICHARD J.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1977-09
- Volume
- 45
- Issue
- 3
- Pages
- 469-479
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2165422128
- Cited by
- 73
- References
- 0
- Citations by year
- 2026: 2 · 2013: 1 · 2012: 1
- FWCI
- 6.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Keywords
- aminoglutethimide, cortisol, dexamethasone, adrenal suppression, glucocorticoid metabolism, drug interactions, dehydroepiandrosterone sulfate, urinary free cortisol, ACTH suppression, metastatic breast cancer, plasma half-life, metabolic clearance rate, negative nitrogen balance
- MeSH terms
- Adrenal Glands, Adrenocorticotropic Hormone, Aminoglutethimide, Breast Neoplasms, Castration, Dehydroepiandrosterone, Dexamethasone, Female, Humans, Hydrocortisone, Nitrogen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review